Unlocking the power of cyclosporine for superior dry eye relief
Wellspring Ophthalmics is a development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye therapy.
Dry eye sufferers have an unmet need and deserve help
Dry eye is under-diagnosed and under-treated. About 30 million people in the U.S. suffer from dry eye, but only about 17 million are diagnosed.
Dry eyes can affect sufferers’ quality of life, may hamper reading, driving ability, computer use, work productivity, etc. and may be associated with increased anxiety, stress and depression.
Only about 1.7 million people in the U.S. are treated with prescription eye drops – and still this market is estimated at over $1.5 billion annually worldwide.
Our Mission
We have patented and formulated an unrivaled cyclosporine dry eye relief therapy.
We aim to license our intellectual property portfolio, including issued and pending patents, to a licensee who will complete development and commercialize our innovation.
Our Science
Our proprietary broad formulation platform is a novel suspension comprising aqueous, amorphous nanodispersions of cyclosporine.
Our flexible formulation platform overcomes known deficiencies of current cyclosporine eye drops, including emulsions and solutions.
Our formulations are designed to have higher bioavailability for better efficacy and improved dry eye relief versus emulsion formulations.
Our preliminary animal bioavailability data confirms higher bioavailability when compared to the market leader.
Our patented suspension formulations can contain much higher concentrations of cyclosporine than formulations comprising emulsions or solutions.
Wellspring Ophthalmics Announces Receiving Its Second Patent for Novel Cyclosporine Dry Eye Therapy
Company Remains Focused on Finding a Licensee for This Proprietary Cyclosporine Platform and Is Encouraged by the Significant Interest To Date MISSION VIEJO, CA, ...
Wellspring Ophthalmics Announces Acquisition of Novel Cyclosporine Dry Eye Therapy Patent Portfolio from Newport Research
Now, Company Concentrates on Finding a Licensee to Complete the Development and Commercialization of This Proprietary Cyclosporine Platform MISSION VIEJO, CA, USA (March 23rd, ...
Newport Research Announces Receiving Patent for Novel Cyclosporine Dry Eye Therapy
Plus, Company Receives Allowance for Second Patent for Innovative Cyclosporine Dry Eye Therapy NEWPORT BEACH, CA, USA (March 16th, 2022) – Today, Newport Research, ...
Contact Us
Please contact us by filling out the form below or by sending us an email or by sending us correspondence to our address.